PT3192524T - Preparação de hgf adequada para tratamento de distúrbios neurológicos - Google Patents
Preparação de hgf adequada para tratamento de distúrbios neurológicosInfo
- Publication number
- PT3192524T PT3192524T PT158400622T PT15840062T PT3192524T PT 3192524 T PT3192524 T PT 3192524T PT 158400622 T PT158400622 T PT 158400622T PT 15840062 T PT15840062 T PT 15840062T PT 3192524 T PT3192524 T PT 3192524T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- preparation suitable
- nervous diseases
- hgf preparation
- hgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014184475 | 2014-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3192524T true PT3192524T (pt) | 2022-02-17 |
Family
ID=55458917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158400622T PT3192524T (pt) | 2014-09-10 | 2015-08-27 | Preparação de hgf adequada para tratamento de distúrbios neurológicos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10213485B2 (pt) |
| EP (1) | EP3192524B1 (pt) |
| JP (2) | JP6281992B2 (pt) |
| KR (1) | KR101950916B1 (pt) |
| CN (1) | CN106714823A (pt) |
| CA (1) | CA2958342C (pt) |
| DK (1) | DK3192524T3 (pt) |
| ES (1) | ES2907125T3 (pt) |
| PT (1) | PT3192524T (pt) |
| WO (1) | WO2016039163A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101950916B1 (ko) * | 2014-09-10 | 2019-02-21 | 크링글파마 가부시키가이샤 | 신경 질환의 치료에 적절한 hgf 제제 |
| US11957713B2 (en) | 2016-10-14 | 2024-04-16 | Children's Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
| US11548936B2 (en) | 2017-01-17 | 2023-01-10 | Children's Medical Center Corporation | Compositions and methods for treating lysosomal storage diseases and disorders |
| KR102245539B1 (ko) * | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
| JP7380670B2 (ja) * | 2018-07-17 | 2023-11-15 | ヘリックスミス カンパニー， リミテッド | Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療 |
| CN109535243B (zh) * | 2019-01-07 | 2019-09-24 | 北京诺思兰德生物技术股份有限公司 | 人肝细胞生长因子突变体及其应用 |
| WO2022241465A1 (en) | 2021-05-14 | 2022-11-17 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| JP3680114B2 (ja) * | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
| JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Ｈｇｆ凍結乾燥製剤 |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| CN100448482C (zh) * | 1999-05-31 | 2009-01-07 | 三菱化学株式会社 | Hgf冻干制剂 |
| JP5442173B2 (ja) * | 2000-09-14 | 2014-03-12 | 敏一 中村 | 筋萎縮性側索硬化症治療剤 |
| US20030176347A1 (en) | 2003-05-14 | 2003-09-18 | Toshikazu Nakamura | Remedies for amyotrophic lateral sclerosis |
| ATE468862T1 (de) * | 2001-07-11 | 2010-06-15 | Maxygen Inc | G-csf konjugate |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| JP4537956B2 (ja) * | 2003-03-26 | 2010-09-08 | クリングルファーマ株式会社 | 喘息治療剤 |
| JP4716873B2 (ja) * | 2003-10-14 | 2011-07-06 | 聰 竹尾 | 知的障害の改善剤 |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| CN101247794B (zh) * | 2005-03-07 | 2012-02-22 | 盟多生化股份公司 | 阿肽地尔的制剂 |
| WO2007122976A1 (ja) | 2006-04-20 | 2007-11-01 | Osaka University | ポリグルタミン病の治療剤又は発病抑制剤 |
| US7935791B2 (en) * | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
| WO2008102452A1 (ja) * | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Ｈｇｆ製剤 |
| WO2008105088A1 (ja) | 2007-02-28 | 2008-09-04 | Keio University | 脊髄損傷治療薬剤 |
| WO2010008023A1 (ja) * | 2008-07-18 | 2010-01-21 | クリングルファーマ株式会社 | 骨延長促進剤 |
| EP2351574B1 (en) * | 2008-10-10 | 2016-08-24 | Kringle Pharma, Inc. | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue |
| CN101785856B (zh) * | 2009-01-22 | 2012-06-06 | 齐鲁制药有限公司 | 稳定等渗的去氨普酶α1或其突变体制剂 |
| JP2011173916A (ja) * | 2011-05-02 | 2011-09-08 | Toshiichi Nakamura | 筋萎縮性側索硬化症治療剤 |
| EP2928486A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia |
| EP2970396B1 (en) * | 2013-03-15 | 2022-02-23 | Biological Mimetics, Inc. | Immunogenic human rhinovirus (hrv) compositions |
| KR101950916B1 (ko) * | 2014-09-10 | 2019-02-21 | 크링글파마 가부시키가이샤 | 신경 질환의 치료에 적절한 hgf 제제 |
-
2015
- 2015-08-27 KR KR1020177009589A patent/KR101950916B1/ko active IP Right Grant
- 2015-08-27 US US15/507,886 patent/US10213485B2/en active Active
- 2015-08-27 PT PT158400622T patent/PT3192524T/pt unknown
- 2015-08-27 CA CA2958342A patent/CA2958342C/en active Active
- 2015-08-27 CN CN201580048600.8A patent/CN106714823A/zh active Pending
- 2015-08-27 ES ES15840062T patent/ES2907125T3/es active Active
- 2015-08-27 WO PCT/JP2015/074310 patent/WO2016039163A1/ja active Application Filing
- 2015-08-27 EP EP15840062.2A patent/EP3192524B1/en active Active
- 2015-08-27 DK DK15840062.2T patent/DK3192524T3/da active
- 2015-08-27 JP JP2016547358A patent/JP6281992B2/ja active Active
-
2017
- 2017-12-08 JP JP2017236414A patent/JP2018044000A/ja active Pending
-
2018
- 2018-12-28 US US16/235,132 patent/US10702582B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2958342A1 (en) | 2016-03-17 |
| US10702582B2 (en) | 2020-07-07 |
| US10213485B2 (en) | 2019-02-26 |
| KR101950916B1 (ko) | 2019-02-21 |
| EP3192524A1 (en) | 2017-07-19 |
| US20170333527A1 (en) | 2017-11-23 |
| WO2016039163A1 (ja) | 2016-03-17 |
| JP2018044000A (ja) | 2018-03-22 |
| JP6281992B2 (ja) | 2018-02-21 |
| CA2958342C (en) | 2019-09-24 |
| KR20170054465A (ko) | 2017-05-17 |
| EP3192524B1 (en) | 2021-12-29 |
| DK3192524T3 (da) | 2022-02-14 |
| US20190117732A1 (en) | 2019-04-25 |
| JPWO2016039163A1 (ja) | 2017-06-22 |
| CN106714823A (zh) | 2017-05-24 |
| ES2907125T3 (es) | 2022-04-22 |
| EP3192524A4 (en) | 2018-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
| GB201701673D0 (en) | Methods of well treatment | |
| HUE060671T2 (hu) | Eljárás fibrotikus betegségek kezelésére | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| PT3192524T (pt) | Preparação de hgf adequada para tratamento de distúrbios neurológicos | |
| HK1258994A1 (zh) | 用於疾病治療的方法 | |
| IL259755B (en) | Methods for the treatment of bees by administration of cannabinoids | |
| HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
| LT3097085T (lt) | Benzoksazinono dariniai, skirti odos ligų gydymui | |
| HK1231386A1 (zh) | 免疫疾病的治療 | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| GB201416832D0 (en) | Methods of treatment | |
| IL249502B (en) | New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins | |
| HK1246679A1 (zh) | 絲蟲病的治療 | |
| HK1243937A1 (zh) | 治療疾病的方法 | |
| GB201520600D0 (en) | Treatment of central nervous tumours | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| IL259381B (en) | Miravegron for the treatment of retinal diseases | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201519841D0 (en) | Treatment of central nervous tumours | |
| GB201504413D0 (en) | Treatment of disease |